Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis

Takanori Shouda, Takafumi Yoshida, Toshikatsu Hanada, Toru Wakioka, Masanobu Oishi, Kanta Miyoshi, Setsuro Komiya, Ken Ichiro Kosai, Yasushi Hanakawa, Koji Hashimoto, Kensei Nagata, Akihiko Yoshimura

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

Immune and inflammatory systems are controlled by multiple cytokines, including ILs and INFs. These cytokines exert their biological functions through Janus tyrosine kinases and STAT transcription factors. One such cytokine, IL-6, has been proposed to contribute to the development of rheumatoid arthritis (RA). We found that STAT3 was strongly tyrosine phosphorylated in synovial tissue of RA patients, but not those with osteoarthritis. Blockade of the IL-6-gp130-JAK-STAT3-signaling pathway might therefore be beneficial in the treatment of RA. We show here that the mRNA for the endogenous cytokine signaling repressor CIS3/SOCS3 is abundantly expressed in RA patients. To determine whether CIS3 is effective in treating experimental arthritis, a recombinant adenovirus carrying the CIS3 cDNA was injected periarticularly into the ankle joints of mice with antigeninduced arthritis or collagen-induced arthritis (CIA). Periarticular injection of CIS3 adenovirus drastically reduced the severity of arthritis and joint swelling compared with control groups. CIS3 was more effective than a dominant-negative form of STAT3 in the CIA model. Thus, induction of CIS3 could represent a new approach for effective treatment of RA.

Original languageEnglish
Pages (from-to)1781-1788
Number of pages8
JournalJournal of Clinical Investigation
Volume108
Issue number12
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Arthritis
Rheumatoid Arthritis
Experimental Arthritis
Cytokines
Adenoviridae
Interleukin-6
STAT Transcription Factors
Janus Kinases
Therapeutics
Ankle Joint
Osteoarthritis
Protein-Tyrosine Kinases
Tyrosine
Immune System
Complementary DNA
Joints
Control Groups
Messenger RNA
Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. / Shouda, Takanori; Yoshida, Takafumi; Hanada, Toshikatsu; Wakioka, Toru; Oishi, Masanobu; Miyoshi, Kanta; Komiya, Setsuro; Kosai, Ken Ichiro; Hanakawa, Yasushi; Hashimoto, Koji; Nagata, Kensei; Yoshimura, Akihiko.

In: Journal of Clinical Investigation, Vol. 108, No. 12, 2001, p. 1781-1788.

Research output: Contribution to journalArticle

Shouda, T, Yoshida, T, Hanada, T, Wakioka, T, Oishi, M, Miyoshi, K, Komiya, S, Kosai, KI, Hanakawa, Y, Hashimoto, K, Nagata, K & Yoshimura, A 2001, 'Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis', Journal of Clinical Investigation, vol. 108, no. 12, pp. 1781-1788. https://doi.org/10.1172/JCI200113568
Shouda, Takanori ; Yoshida, Takafumi ; Hanada, Toshikatsu ; Wakioka, Toru ; Oishi, Masanobu ; Miyoshi, Kanta ; Komiya, Setsuro ; Kosai, Ken Ichiro ; Hanakawa, Yasushi ; Hashimoto, Koji ; Nagata, Kensei ; Yoshimura, Akihiko. / Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. In: Journal of Clinical Investigation. 2001 ; Vol. 108, No. 12. pp. 1781-1788.
@article{00f51f255e744ac99821832b5fddcca7,
title = "Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis",
abstract = "Immune and inflammatory systems are controlled by multiple cytokines, including ILs and INFs. These cytokines exert their biological functions through Janus tyrosine kinases and STAT transcription factors. One such cytokine, IL-6, has been proposed to contribute to the development of rheumatoid arthritis (RA). We found that STAT3 was strongly tyrosine phosphorylated in synovial tissue of RA patients, but not those with osteoarthritis. Blockade of the IL-6-gp130-JAK-STAT3-signaling pathway might therefore be beneficial in the treatment of RA. We show here that the mRNA for the endogenous cytokine signaling repressor CIS3/SOCS3 is abundantly expressed in RA patients. To determine whether CIS3 is effective in treating experimental arthritis, a recombinant adenovirus carrying the CIS3 cDNA was injected periarticularly into the ankle joints of mice with antigeninduced arthritis or collagen-induced arthritis (CIA). Periarticular injection of CIS3 adenovirus drastically reduced the severity of arthritis and joint swelling compared with control groups. CIS3 was more effective than a dominant-negative form of STAT3 in the CIA model. Thus, induction of CIS3 could represent a new approach for effective treatment of RA.",
author = "Takanori Shouda and Takafumi Yoshida and Toshikatsu Hanada and Toru Wakioka and Masanobu Oishi and Kanta Miyoshi and Setsuro Komiya and Kosai, {Ken Ichiro} and Yasushi Hanakawa and Koji Hashimoto and Kensei Nagata and Akihiko Yoshimura",
year = "2001",
doi = "10.1172/JCI200113568",
language = "English",
volume = "108",
pages = "1781--1788",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis

AU - Shouda, Takanori

AU - Yoshida, Takafumi

AU - Hanada, Toshikatsu

AU - Wakioka, Toru

AU - Oishi, Masanobu

AU - Miyoshi, Kanta

AU - Komiya, Setsuro

AU - Kosai, Ken Ichiro

AU - Hanakawa, Yasushi

AU - Hashimoto, Koji

AU - Nagata, Kensei

AU - Yoshimura, Akihiko

PY - 2001

Y1 - 2001

N2 - Immune and inflammatory systems are controlled by multiple cytokines, including ILs and INFs. These cytokines exert their biological functions through Janus tyrosine kinases and STAT transcription factors. One such cytokine, IL-6, has been proposed to contribute to the development of rheumatoid arthritis (RA). We found that STAT3 was strongly tyrosine phosphorylated in synovial tissue of RA patients, but not those with osteoarthritis. Blockade of the IL-6-gp130-JAK-STAT3-signaling pathway might therefore be beneficial in the treatment of RA. We show here that the mRNA for the endogenous cytokine signaling repressor CIS3/SOCS3 is abundantly expressed in RA patients. To determine whether CIS3 is effective in treating experimental arthritis, a recombinant adenovirus carrying the CIS3 cDNA was injected periarticularly into the ankle joints of mice with antigeninduced arthritis or collagen-induced arthritis (CIA). Periarticular injection of CIS3 adenovirus drastically reduced the severity of arthritis and joint swelling compared with control groups. CIS3 was more effective than a dominant-negative form of STAT3 in the CIA model. Thus, induction of CIS3 could represent a new approach for effective treatment of RA.

AB - Immune and inflammatory systems are controlled by multiple cytokines, including ILs and INFs. These cytokines exert their biological functions through Janus tyrosine kinases and STAT transcription factors. One such cytokine, IL-6, has been proposed to contribute to the development of rheumatoid arthritis (RA). We found that STAT3 was strongly tyrosine phosphorylated in synovial tissue of RA patients, but not those with osteoarthritis. Blockade of the IL-6-gp130-JAK-STAT3-signaling pathway might therefore be beneficial in the treatment of RA. We show here that the mRNA for the endogenous cytokine signaling repressor CIS3/SOCS3 is abundantly expressed in RA patients. To determine whether CIS3 is effective in treating experimental arthritis, a recombinant adenovirus carrying the CIS3 cDNA was injected periarticularly into the ankle joints of mice with antigeninduced arthritis or collagen-induced arthritis (CIA). Periarticular injection of CIS3 adenovirus drastically reduced the severity of arthritis and joint swelling compared with control groups. CIS3 was more effective than a dominant-negative form of STAT3 in the CIA model. Thus, induction of CIS3 could represent a new approach for effective treatment of RA.

UR - http://www.scopus.com/inward/record.url?scp=0035667907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035667907&partnerID=8YFLogxK

U2 - 10.1172/JCI200113568

DO - 10.1172/JCI200113568

M3 - Article

C2 - 11748261

AN - SCOPUS:0035667907

VL - 108

SP - 1781

EP - 1788

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -